Pembrolizumab + Carboplatin + Pemetrexed

COMBINATION_PRODUCT2 trials

Sponsors

Phanes Therapeutics, Xencor, Inc.

Conditions

Non Small Cell Lung CancerNonsquamous Non-small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Phase 1

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

RecruitingNCT05431270

Phanes TherapeuticsNon Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma

Start: 2022-08-11End: 2028-08-31Target: 40Updated: 2025-01-31

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

TerminatedNCT06173505

Xencor, Inc.Nonsquamous Non-small Cell Lung Cancer

Start: 2023-12-27End: 2025-12-29Updated: 2026-03-13

Related Papers

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer

Future Oncology2023-05-185 citations

779 A phase I, dose escalation and expansion study of PT199, a next generation CD73 monoclonal antibody, administered alone and in combination with a PD-1 Inhibitor in adult patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2022-11-011 citations